Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery-Reference-Cited by-同舟云学术

Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery

Published:2023-11 Issue: Volume:148 Page:155689
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Kokkorakis Michail,Katsarou Angeliki,Katsiki Niki,Mantzoros Christos S.

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference292 articles.

1. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on;Boutari;Metabolism,2022

2. Obesity and the risk of cardiometabolic diseases;Valenzuela;Nat Rev Cardiol,2023

3. Obesity and cardiovascular disease: a scientific statement from the American Heart Association;Powell-Wiley;Circulation,2021

4. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics;Polyzos;Metabolism,2019

5. The key role of inflammation in the pathogenesis and management of obesity and CVD;Boutari;Metabolism,2023

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of patients with the cardio renal liver metabolic syndrome: The need for a multidisciplinary approach in research, education and practice;Metabolism;2024-10

2. Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist;Expert Review of Gastroenterology & Hepatology;2024-08-02

3. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges;Metabolism;2024-05

4. Bariatric surgery, through beneficial effects on underlying mechanisms, improves cardiorenal and liver metabolic risk over an average of ten years of observation: A longitudinal and a case-control study;Metabolism;2024-03

5. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies;Pharmacological Reviews;2024-01-30